{"id":48438,"date":"2025-11-17T14:31:52","date_gmt":"2025-11-17T06:31:52","guid":{"rendered":"https:\/\/flcube.com\/?p=48438"},"modified":"2025-11-17T14:31:52","modified_gmt":"2025-11-17T06:31:52","slug":"nmpa-launches-pilot-program-to-cut-review-time-for-overseas%e2%80%91manufactured-drug-supplementary-applications","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48438","title":{"rendered":"NMPA Launches Pilot Program to Cut Review Time for Overseas\u2011Manufactured Drug Supplementary Applications"},"content":{"rendered":"\n

The National Medical Products Administration (NMPA)<\/strong> issued a formal notice today announcing a pilot program<\/strong> aimed at streamlining the review and approval process for supplementary applications of overseas\u2011manufactured chemical drugs<\/strong>. The initiative empowers pilot departments in 14 provinces and municipalities<\/strong> to provide pre\u2011submission services<\/strong> to domestic responsible persons (DRPs) for major changes to such products.<\/p>\n\n\n\n

What the Pilot Changes<\/h2>\n\n\n\n
Aspect<\/th>Current Rule<\/th>Pilot Program Rule<\/th><\/tr><\/thead>
Scope<\/strong><\/td>All supplementary applications for overseas\u2011manufactured chemical drugs.<\/td>Applications that receive pre\u2011submission guidance<\/strong>, meet full dossier requirements and do not trigger an overseas registration inspection<\/strong>.<\/td><\/tr>
Review Timeline<\/strong><\/td>Up to 200 working days<\/strong>.<\/td>Reduced to 60 working days<\/strong> once the pre\u2011submission service is completed.<\/td><\/tr>
Service Provider<\/strong><\/td>Centralized NMPA review.<\/td>Pilot units<\/strong> (provincial\/municipal drug\u2011regulation offices) deliver pre\u2011submission guidance and dossier\u2011preparation assistance<\/strong>.<\/td><\/tr>
Inspection Trigger<\/strong><\/td>Automatic overseas registration inspection for many supplements.<\/td>CDE<\/strong> (Center for Drug Evaluation) decides if an inspection is needed; if so, CFDI<\/strong> (Center for Food and Drug Inspection) conducts it.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

How the New Workflow Works<\/h2>\n\n\n\n
    \n
  1. Pre\u2011Submission Service<\/strong> \u2013 The pilot unit in the applicant\u2019s jurisdiction works with the Domestic Responsible Person (DRP)<\/strong> to review the supplement dossier, advise on regulatory gaps, and ensure completeness.<\/li>\n\n\n\n
  2. Submission to CDE<\/strong> \u2013 After the pilot unit signs off, the Marketing Authorization Holder (MAH)<\/strong> files the supplementary application with the NMPA\u2019s Center for Drug Evaluation (CDE)<\/strong>.<\/li>\n\n\n\n
  3. CDE Assessment<\/strong> \u2013 The CDE evaluates whether an overseas registration inspection<\/strong> is required based on the nature of the change and existing data.<\/li>\n\n\n\n
  4. Inspection (if needed)<\/strong> \u2013 When required, the Center for Food and Drug Inspection (CFDI)<\/strong> organizes and executes the overseas inspection.<\/li>\n\n\n\n
  5. Decision<\/strong> \u2013 If no inspection is needed, the CDE proceeds to a final decision within 60 working days<\/strong>.<\/li>\n<\/ol>\n\n\n\n

    Strategic Implications<\/h2>\n\n\n\n